CLEC4C and systemic lupus erythematosus: In addition, a single dose of a humanized mAb that binds BDCA-2 decreased IFN expression and improved cutaneous lupus disease activity in SLE patients (Chaichian et al, 2019; Furie et al, 2019, 2022).